| abstract |
The present invention is also directed to small molecule compounds, IL-1 beta antibodies or IL-1 receptor antibodies, such as the IL-1 beta binding molecules described herein, that interfere with the interaction of the IL- IL-1 [beta] -ligand / IL-1 receptor such as an IL-1 [beta] binding compound or an IL-1 receptor binding compound, and / or an RNA compound that decreases the concentration of an IL- Novel uses of the compounds (herein referred to as "IL-1 beta compounds") in the treatment and / or prevention of auto-inflammatory syndromes such as pediatric rheumatoid arthritis or adult rheumatoid arthritis syndrome and mammalian, Inflammatory syndromes such as pediatric rheumatoid arthritis or adult rheumatoid arthritis syndrome. |